North Carolina-based Merakris Therapeutics received US FDA Fast Track designation status for MTX-001, its lead biologic candidate, for the treatment of chronic, non-infected venous stasis ulcers, commonly referred to as venous leg ulcers (VLUs). MTX-001 is a first-in-class injectable biologic purified from cell-free amniotic fluid, designed to deliver a multi-component profile of regenerative bioactive factors to address impaired tissue repair in chronic wounds.
Fast Track designation enables more frequent FDA interactions throughout development and creates eligibility for rolling review of a future Biologics License Application (BLA), allowing completed sections to be submitted and assessed before the full dossier is finalized. The designation also positions MTX-001 for potential Priority Review, subject to future FDA determination and clinical results.
The clinical data underpinning the designation come primarily from Part 1 of the multicenter Phase II study NCT04647240, published in the International Wound Journal in March 2025. In that cohort of adult patients with chronic, refractory VLUs, 66.7% achieved complete wound closure by the one-month post-trial follow-up. Among patients completing the full 12-week treatment course, the average reduction in ulcer area was 83.7%. No treatment-related adverse events were reported across weekly or biweekly dosing arms. An April 2026 company update reported cumulative safety and clinical data from 95 treated subjects across both the Phase II study and an Expanded Access Program (NCT06730022) for cutaneous wounds, with response patterns described as consistent with Part 1 findings.
Research context
VLUs affect an estimated 600,000 to 1 million patients annually in the US, generating substantial healthcare expenditure through prolonged treatment, recurrence, hospitalization, and lost productivity. Standard-of-care approaches — principally compression therapy and wound dressings — leave a meaningful proportion of patients without durable healing. No injectable biologic has been approved specifically for this indication.
The competitive field includes amniotic membrane and tissue-derived products, several of which have been regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271 rather than as formal biologics requiring BLA approval. MTX-001 is pursuing the BLA pathway as a purified, injectable cell-free preparation, which distinguishes it from amniotic membrane allografts such as those marketed by MiMedx and Organogenesis. Becaplermin (Regranex), a platelet-derived growth factor approved for diabetic neuropathic ulcers, holds no VLU indication. The absence of an approved injectable biologic in VLUs provides the regulatory rationale the FDA applied in granting Fast Track status.
Merakris has indicated that earlier FDA engagement on chemistry, manufacturing, and controls (CMC) is among the most material practical benefits of the designation for a biologic product, where manufacturing complexity can represent a development bottleneck. Rolling BLA review would allow CMC and clinical modules to enter formal assessment before Phase III data are complete, potentially compressing the overall regulatory timeline.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team
Explore more at AllSci News: https://allsci.com/news/